Screening Study for Participants With Malignant Tumors

General Inclusion Criteria:

• Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE)tumor specimen meeting criteria defined in the protocol

• Considered by principal investigator (PI) to be a candidate for a linked clinicaltrial with an investigational medicinal product, and that the participant has theawareness and willingness to participate in said trial

Inclusion Criteria for Participants with Stage III NSCLC

• Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamoushistology based on 8th edition of the American Joint Committee on Cancer (AJCC) andUnion for International Cancer Control (UICC) cancer staging system

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Inclusion Criteria for Participants with Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC Requiring Adjuvant Treatment

• Stage II, IIIA, or select IIIB (T3N2 only) NSCLC based on the 8th edition of theAJCC and UICC cancer staging system (Amin et al. 2017)

• Considered eligible for curative intent surgery (complete resection with allsurgical margins testing negative for tumor)

• Screening within Study BX43361, using a pretreatment biopsy, is encouraged to beperformed as early in the participant treatment pathway as possible to ensure theparticipant is potentially eligible for all cohorts, and should meet guidelines asdefined by the protocol

• Representative FFPE tumor specimen obtained prior to the start of any treatment

• ECOG Performance Status of 0 or 1

General Exclusion Criteria:

• History of malignancy other than NSCLC within 5 years prior to screening, except formalignancies with a negligible risk of metastasis or death

• Any condition that may affect the interpretation of study results

• Significant liver or cardiovascular disease

• Prior allogenic stem-cell or solid-organ transplantation